Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
Grenet J, Jain A, Burkart M, Waksal J, Famulare C, Numan Y, Stahl M, Mckinnell Z, Ball B, Ma X, Christos P, Ritchie E, Samuel M, Kaner J, Lee S, Goldberg A, Dinner S, Sweet K, Roboz G, Desai P. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood 2021, 138: 32. DOI: 10.1182/blood-2021-145947.Peer-Reviewed Original ResearchRelapse free survivalEntity's Board of DirectorsCPX-351Overall survivalFrontline therapyTreated ptsMultivariate analysisRetrospective studySurvival advantageSubgroup analysisMedian relapse free survivalMulti-center retrospective studyMultivariate Cox proportional hazards regression analysisCox proportional hazards regression analysisVariability of treatment responseMultivariate subgroup analysisNewly diagnosed AMLKaplan-Meier survival analysisMultivariate logistic regression analysisProportional hazards regression analysisMulticenter retrospective studyLog-rank testAcute myeloid leukemiaHazards regression analysisPrimary outcome variable
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply